November 25, 2016 - By Winifred Garcia · 0 Comments
The stock of Avexis Incorporated (NASDAQ:AVXS) registered a decrease of 19.18% in short interest. AVXS’s total short interest was 1.25 million shares in November as published by FINRA. Its down 19.18% from 1.55 million shares, reported previously. With 224,800 shares average volume, it will take short sellers 6 days to cover their AVXS’s short positions. The short interest to Avexis Incorporated’s float is 12.11%. The stock increased 7.12% or $3.95 on November 23, hitting $59.44. AveXis Inc (NASDAQ:AVXS) has risen 158.21% since April 22, 2016 and is uptrending. It has outperformed by 152.80% the S&P500.
AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The company has a market cap of $1.76 billion. The Firm operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. It currently has negative earnings. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Out of 4 analysts covering AveXis (NASDAQ:AVXS), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. AveXis has been the topic of 5 analyst reports since May 13, 2016 according to StockzIntelligence Inc. The stock has “Market Perform” rating given by Wells Fargo on Friday, July 15. Jefferies maintained the stock with “Buy” rating in Monday, September 19 report. The rating was initiated by Bank of America on Friday, October 21 with “Buy”. The stock of AveXis Inc (NASDAQ:AVXS) earned “Buy” rating by Goldman Sachs on Friday, May 13. Jefferies upgraded AveXis Inc (NASDAQ:AVXS) on Friday, August 12 to “Buy” rating.
Another recent and important AveXis Inc (NASDAQ:AVXS) news was published by Marketwatch.com which published an article titled: “AveXis started at hold with $65 stock price target at Stifel Nicolaus” on January 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia